相关实验视频
Updated: Jul 4, 2025

11:28
Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
18.0K
氧化-循环GMP在Ang II诱导的高极化中的作用在牛大动脉内皮细胞系 (BAE-1) 中
Chinar M Mohammed1, Omar A M Al-Habib2
1Department of Biology, Faculty of Science, University of Zakho, Duhok, Kurdistan Region Iraq.
Cytotechnology
|February 2, 2024
概括
ангиотензин II (Ang II) 通过激活AT2受体触发血管扩张,从而释放氧化 (NO),并刺激内皮细胞中的 (K) 电流.
科学领域:
- 心血管生理学心血管生理学
- 内皮细胞生物学 内皮细胞生物学
- 分子药理学分子药理学
背景情况:
- ангиотензин II (Ang II) 是一种调节血压的关键激素.
- 内皮细胞在血管调节中起着至关重要的作用.
- Ang II介导血管扩张的具体机制需要进一步阐明.
研究的目的:
- 研究 ангиотензин II (Ang II) 受体,特别是AT2在调解血管扩张中的作用.
- 为了确定氧化 (NO) 途径是否参与Ang II诱导的血管扩张.
- 分析Ang II对内皮细胞中 (K) 通道活性的影响.
主要方法:
- 西方涂抹用于检测牛大动脉内皮细胞 (BAE-1) 中的 ангиотензинII受体 (AT2) 表达.
- 格雷斯试剂测定量化氧化 (NO) 生产量.
- 细胞附着的补丁电生理学记录膜电流和K通道活动.
主要成果:
- 牛大动脉内皮细胞 (BAE-1) 表达AT2受体,在瓦尔萨坦 (AT1抑制剂) 存在时观察到水平升高.
- ангиотензин II (Ang II) 治疗以度依赖的方式增加了氧化 (NO) 水平.
- 补丁研究表明,Ang II,特别是在AT1受体阻塞后,增强了K电流和导电量,这种效应被AT2受体抑制剂 (PD1231777) 逆转.
结论:
- ангиотензин II (Ang II) 主要通过激活AT2受体诱导血管扩张.
- AT2受体调解NO的释放,有助于血管扩张效应.
- ангиотензин II (Ang II) 刺激K电流,这表明它在调节内皮细胞膜潜力和血管度方面的作用.
相关概念视频
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Antianginal Drugs: Nitrates and β-Blockers
592
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
592
Antihypertensive Drugs: Angiotensin II Receptor Blockers
734
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
734
Antihypertensive Drugs: Vasodilators
525
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
525
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515

